DOI: https://doi.org/10.22141/2309-8147.5.2.2017.172459

PREDICTORS OF DIABETIC RETHYOPATHY PROGRESSING AT METABOLIC SYNDROME

V. Serdyuk, V. Іshchenko

Abstract


Summary. We studied the biochemical parameters of carbohydrate metabolism and insulin resistance in 59 patients with type 2 diabetes mellitus (DM) (mean age 58.2 + 0.99 years, the average length of diabetes 9.19 + 0.16 years) at different stages of diabetic retinopathy (DR).
Research methods included the dispersive analysis of variances and the mathematic law of the binomial distribution.
Our results showed that DR is forming on the fi eld of fasting hyperglycemia, abnormal postprandial hyperglycemia, decompensation of DM (according to glycated hemoglobin). Further progression of DR statistically signifi cantly associated with a relative frequency increase of hyperinsulinemia.
Conclusion. Metabolic syndrome hyperinsulinemia together with glycated hemoglobin in patients with type 2 DM can be viewed as predictors of DR progression.


Keywords


diabetic retinopathy, metabolic syndrome

References


Кирилюк М. Л. Медикаментозное лечение и профилактика диабетической ретинопатии при сахарном диабете 1 типа / М. Л. Кирилюк // Міжнародний ендокринологічний журнал. – 2012. – № 5 (45). – С. 70–75.

Кирилюк М. Л. Роль чинників росту у розвитку доброякісної гіперплазії передміхурової залози та їх зв’язок із метаболічним синдромом / М. Л. Кирилюк, Ф. І. Костєв, А. В.Підаєв, С. С. Шаталюк //Клінічна ендокринологія і ендокринна хірургія. – 2012. – № 3 (40). – С. 3–8.

Малачкова Н. В. Уровень гликемии и инсулинорезистентности у больных с сахарным диабетом 2-го типа, диабетической ретинопатией и ожирением / Н. В. Малачкова, И. В. Комаровская, М. Л. Кирилюк // Міжнародний ендокринологічний журнал. – 2017. – № 13 (3).– С. 27–32. – DOI: 10.22141/2224-0721.13.3.2017.104108.

Поляков И. В. Практическое пособие по медицинской статистике. / И. В. Поляков, Н. С. Соколова. – Л.: Медицина, 1975. – 125 с.

Arcidiacono B. Insulin Resistance and Cancer Risk: An Overview of the Pathogenetic Mechanisms /B. Arcidiacono, S. Iritano, A. Nocera [et al.] // Experimental Diabetes Research. – 2012. – Vol. 2012. – 12 p. – DOI: http://dx.doi.org/10.1155/2012/789174.

Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) // JAMA. – 2001. – № 285. – Р. 2486–2497.

Hirsch I. B. Beyond hemoglobin A1c–need for additional markers of risk for diabetic microvascular complications / I. B. Hirsch, M. Brownlee // JAMA. – 2010. – № 303. – P. 2291–2292.

Inzucchi S. E. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes / S. E. Inzucchi, R. M. Bergenstal, J. B. Buse [et al.] // Diabetes Care. – 2015. – Vol. 38 (1). – Р. 140–149. – DOI: 10.2337/dc14-2441.

Kaaks R. Energy balance and cancer: the role of insulin and insulin-like growth factor-I / R. Kaaks, A. Lukanova // Proceedings of the Nutrition Society. – 2001. – Vol. 60 (1). – P. 91–106.

Klein R. The epidemiology of diabetic retinopathy. In: Duh E., ed. Diabetic retinopathy / R. Klein. – Totowa, NJ: Humana, 2008. – P. 67–107.

Klein R. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes / R. Klein, B. E. Klein, S. E. Moss [et al.] // Ophtalmology. – 1998. – № 105. – P. 1801–1805.

Kohner E. M. Screening for diabetic retinopathy in Europe: A fi eld handbook / E. M. Kohner, M. Porta. – Boehringer Mannheim, Italy.– 1992.

Nathan D. M. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial. Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005) / D. M. Nathan, B. Zinman, P. A. Cleary [et al.] // Arch. Intern. Med. – 2009. – Vol. 169. – P. 1307–1316.

Paranova A. Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes / A. Paranova, I. Iliev, M. Filipponi [et al.] // Clin Endocrinol Metab. – 2004. – Vol. 89 (9). – P. 4371–4376. – DOI: 10.1210/jc.2003-032076.

Pittas A. G. Adipocytocines and Insulin Resistance /A. G. Pittas, N. A. Joseph, A. S. Greenberg // J. Clin. Endocrin. Metab. – 2004. – Vol. 89 (2). – P. 447–452. 16. Reaven G. M. Banting Lecture. Role of insulin resistance in human disease / G. M. Reaven // Diabetes. – 1988. – Vol. 37. – P. 1595–1607.

Scott M. G. Diagnosis and Management of the Metabolic Syndrome / M. G. Scott, I. J. Cleeman, R. S. Daniels [еt al.] // Circulation. – 2005. – 112.

– Р. 2735–2752. – DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.105.169404.

Stattin P. Circulating insulin–like growth factor–I and benign prostatic hyperplasia – a prospective study /P. Stattin, R. Kaaks, E. Riboli [et al.] // Scandinavian journal of urology and nephrology. – 2001. – Vol. 35 (2). – P. 122–126.

Testa M. A. Clinical predictors of retinopathy and its progression in patients with type 1 diabetes during CSII and conventional insulin treatment / M. A. Testa, J. E. Puklin, R. S. Sherwin [et al.] // Diabetes. – 1985. – Vol. 34 (Suppl. 3). – P. 61–68.

Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation (WHO/NMH/CHP/CPM/11.1). – World Health Organization; 2011. – 25 p.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта